| Name | L-BUTHIONINE-(S,R)-SULFOXIMINE |
| Description | L-Buthionine-(S,R)-sulfoximine, a cell-permeable and irreversible inhibitor of γ-glutamylcysteine synthetase (Ki <100 μM), induces oxidative stress in cells by depleting GSH. |
| In vitro | IC50 values (microM) for L-buthionine-S,R-sulfoximine (BSO) on melanoma, breast and ovarian tumor specimens were 1.9, 8.6, and 29, respectively. The IC90 for melanoma was 25.5 microM, a level 20-fold lower than steady-state levels achieved clinically [1]. GSH loss induced by L-buthionine-S,R-sulfoximine (BSO) leads to overproduction of reactive oxygen species (ROS) and triggers apoptosis of MYCN-amplified neuroblastoma cells [2]. |
| In vivo | Systemic BSO administration selectively altered GSH homeostasis and EAAT3 levels in the mice cerebellum. Intraperitoneal treatment of mice with 6?mmol/kg of BSO depleted GSH and GSSG in the liver at 2?h of treatment [3]. |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : Insoluble
H2O : 50 mg/mL (224.91 mM), Sonication is recommended.
|
| Keywords | Ferroptosis | stress | GSH | Inhibitor | eye-spot | inhibit | oxidative | L-BUTHIONINE-SULFOXIMINE | glutamylcysteine | LBUTHIONINE(S,R)SULFOXIMINE | L BUTHIONINE (S,R) SULFOXIMINE | L-BSO | L-Buthionine sulfoximine | BSO |
| Inhibitors Related | Curcumin | L-Cystine |
| Related Compound Libraries | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cell Cycle Compound Library |
United States
